StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultNov 13, 2026, 04:38 PM

Annovis Bio Q3 Net Loss Widens to $9.46M on Soaring R&D Costs

AI Summary

Annovis Bio, Inc. filed its quarterly report for the period ended September 30, 2026. The company reported a net loss of $9.46 million for the third quarter of 2026, an increase from $7.26 million in the same period of 2025. Operating expenses more than doubled to $16.97 million, driven primarily by a significant increase in research and development costs. The company's cash position has dwindled to $2.82 million, and it acknowledges substantial doubt about its ability to continue as a going concern, planning to raise additional capital.

Key Highlights

  • Annovis Bio reported a net loss of $9.46 million for Q3 2026, compared to $7.26 million in Q3 2025.
  • Total operating expenses increased to $16.97 million in Q3 2026 from $7.43 million in Q3 2025.
  • Research and development expenses significantly rose to $15.78 million in Q3 2026 from $6.29 million in Q3 2025.
  • Cash and cash equivalents decreased to $2.82 million as of September 30, 2026, from $19.53 million as of December 31, 2025.
  • Warrant liability increased substantially to $12.47 million as of September 30, 2026, from $0.60 million as of December 31, 2025.
  • The company has accumulated a deficit of $205.6 million as of September 30, 2026.
  • Net loss per share was $(0.22) for Q3 2026, compared to $(0.37) for Q3 2025.